News & Updates
Filter by Specialty:
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
12 Oct 2023How to prevent CVD and early death? Take a walk
People who walk as few as approximately 2,500 and 2,700 steps per day appear to enjoy significantly lower risks of mortality and cardiovascular disease (CVD), with greater risk reductions seen when walking up to about 8,800 and 7,100 steps per day, respectively, suggests a study.
How to prevent CVD and early death? Take a walk
12 Oct 2023Age, motion sickness tied to chemo-induced nausea, vomiting in children with cancer
In children with cancer receiving chemotherapy, factors such as age and susceptibility to motion sickness are associated with the risk of acute chemotherapy-induced nausea (CIN), reports a study.
Age, motion sickness tied to chemo-induced nausea, vomiting in children with cancer
11 Oct 2023Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?
Cancer patients who are being treated with chemotherapy are susceptible to chemotherapy-induced nausea and vomiting (CINV), and they continue to experience these side effects despite being administered with antiemetics, a study has shown.